Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Condition(s)

Leukemia

Age Group

10-17 years 18-26 years 27 years and older

Phase(s)

Biological

UCART19

Trial Summary & Details

Ages: 16 Years to 69 Years
Condition: B-cell Acute Lymphoblastic Leukemia

The purpose of this study is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen.

Status

Recruiting

Location(s)

Massachusetts General Hospital, Boston, MA
Hospital of the University of Pennsylvania, Philadelphia, PA
University of Texas MD Anderson Cancer Center, Houston, TX
Hôpital Saint-Antoine, PARIS Cedex 12, France
Hôpital Saint-Louis, Paris, France
King's College Hospital NHS Foundation Trust, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom

Sponsor/Collaborators:
Institut de Recherches Internationales Servier, ADIR - a Servier Group Company

Contact

Institut de Recherches Internationales Servier
+33 1 55 72 43 66
clinicaltrials@servier.com

Find out more